Patient characteristics
| . | IDR group (n = 532) . | DNR group (n = 525) . | P . |
|---|---|---|---|
| Median age, y (range) | 47 (15-64) | 47 (15-64) | .781 |
| ≤ 50 | 310 | 306 | .996 |
| > 50 | 222 | 219 | |
| Median WBC count, ×109/L (range) | 13.7 (0.1-382) | 15.3 (0.1-334) | .769 |
| ≤ 20 × 109/L | 304 | 297 | .427 |
| 20= ≤ 50 × 109/L | 95 | 104 | |
| > 50 × 109/L | 125 | 121 | |
| Unknown | 8 | 3 | |
| FAB type | |||
| M0 | 30 | 30 | .997 |
| M1 | 95 | 94 | |
| M2 | 232 | 233 | |
| M4 | 100 | 100 | |
| M5 | 56 | 51 | |
| M6 | 17 | 16 | |
| M7 | 2 | 1 | |
| Cytogenetic group | |||
| Favorable | 128 | 119 | .561 |
| Intermediate | 335 | 346 | |
| Adverse | 49 | 44 | |
| Unknown | 20 | 16 | |
| MPO-positive blasts, % | |||
| < 50 | 169 | 187 | .330 |
| ≥ 50 | 307 | 292 | |
| Unknown | 56 | 46 | |
| Performance status | |||
| 0, 1, 2 | 512 | 509 | .524 |
| 3 | 20 | 16 | |
| . | IDR group (n = 532) . | DNR group (n = 525) . | P . |
|---|---|---|---|
| Median age, y (range) | 47 (15-64) | 47 (15-64) | .781 |
| ≤ 50 | 310 | 306 | .996 |
| > 50 | 222 | 219 | |
| Median WBC count, ×109/L (range) | 13.7 (0.1-382) | 15.3 (0.1-334) | .769 |
| ≤ 20 × 109/L | 304 | 297 | .427 |
| 20= ≤ 50 × 109/L | 95 | 104 | |
| > 50 × 109/L | 125 | 121 | |
| Unknown | 8 | 3 | |
| FAB type | |||
| M0 | 30 | 30 | .997 |
| M1 | 95 | 94 | |
| M2 | 232 | 233 | |
| M4 | 100 | 100 | |
| M5 | 56 | 51 | |
| M6 | 17 | 16 | |
| M7 | 2 | 1 | |
| Cytogenetic group | |||
| Favorable | 128 | 119 | .561 |
| Intermediate | 335 | 346 | |
| Adverse | 49 | 44 | |
| Unknown | 20 | 16 | |
| MPO-positive blasts, % | |||
| < 50 | 169 | 187 | .330 |
| ≥ 50 | 307 | 292 | |
| Unknown | 56 | 46 | |
| Performance status | |||
| 0, 1, 2 | 512 | 509 | .524 |
| 3 | 20 | 16 | |
Values are number of patients unless otherwise indicated.
IDR indicates idarubicin; DNR, daunorubicin; WBC, white blood cell count; FAB, French-American-British classification; and MPO, myeloperoxidase.